Intellia: ReCode to secure funds for cystic fibrosis gene correction treatments
ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research programme.
Read full article »
Intellia Therapeutics is a Massachusetts-based biotechnology company that researches and develops genome editing therapies to treat genetic and oncological diseases.
Read more